{
  "model": "chatgpt-gpt-5.3-codex",
  "taskId": "tumor-vaccine-ici",
  "runIndex": 3,
  "result": {
    "text": "- [x] `output/study_overview.json` written\n- [x] `output/quantitative_findings.json` written\n- [x] `output/claim_audit.json` written\n- [x] `output/public_summary.json` written",
    "thoughts": "**Investigating JSON issues**\n\nIt seems that the `public_summary` read_file function is truncating mid-line due to a newline character, which is causing invalid JSON. Specifically, line 3 ends with \"MHC-I\" and then a newline before the closing quote, indicating an issue. We wrote the file correctly without a newline, but it still truncates at the same point. Maybe there's a literal newline in the middle? Since the output shows a cut-off at \"MHC-I,\" it suggests there's a character limit affecting the read_file function.**Examining line truncation issues**\n\nThere's a 60-line limit, and line 3 is quite large. This might be causing truncation in the tool display, possibly due to line wrapping. However, grep_search shows the line complete. It seems like read_file could be displaying a partial line because of an internal line limit. It also doesn’t show closing quotes or commas at line 3. I wonder if I can verify the JSON's validity without a parser by using grep to check for closing quotes and commas. The file appears valid; read_file might not display long lines properly, so I’ll assume it’s fine.**Evaluating JSON compliance**\n\nIt seems we're close to violating the guideline about writing output files only if there's a concrete JSON or schema problem. While I found a potential quote issue, it doesn’t seem to affect the JSON itself. The `claim_audit` schema requires exact quotes, and we’ve adjusted them to match the full line with proper punctuation. We're ensuring that `public_summary` aligns with the schema too. I need to validate items like `what_is_new`, `why_caution`, and `open_questions`—all look good! Lastly, I need to check evidence quotes for the minimum requirement of ten.**Reviewing quantitative findings**\n\nI’m checking the quantitative findings: each `evidence_line_refs` array can have a maximum of 3, and we have that covered. For findings, the minimum is 5, and we currently have 6. The controls requirement of at least 2 is also met, as we have 4. I need to ensure `additionalProperties` is false, and our objects have no extra keys. I’m also concerned about the `claim_audit` quotes matching exactly; I noted leading characters from the report and made sure our lines align, including the spaces that can affect the markdown.**Confirming outputs and validity**\n\nI need to ensure that spaces and formatting match in our quotes, especially for lines that include leading pipes. For instance, line 28 correctly reflects the original line with all spaces included. Lines 29, 30, and 32 follow a similar format, which is great! Now, I need to verify that the output directory contains the four required files. I should check that the `public_summary` file is valid JSON, especially since read_file appeared truncated. I’ll use grep to confirm closing quotes and commas. After all this, I can stop the tools and provide a completion checklist!",
    "steps": [
      {
        "step": 1,
        "modelVersion": "chatgpt-gpt-5.2-2025-12-11",
        "thoughts": "I'm planning to read TASK.md and then follow the instructions within. I think I should use some tools for this as well. Maybe doing some parallel reading between TASK and the schema list would be beneficial. It's good to have a structured approach to take in all that information. I wonder how I can best utilize the tools to streamline the process since understanding both documents seems essential for moving forward effectively.",
        "toolCalls": [
          {
            "toolName": "read_file",
            "input": {
              "file_path": "TASK.md",
              "offset": 0,
              "limit": 200
            },
            "output": "L1: # Agent Task\nL2: \nL3: Task id: tumor-vaccine-ici\nL4: Task title: mRNA tumor sensitization for checkpoint blockade\nL5: Reference paper: SARS-CoV-2 mRNA vaccines sensitize tumours to immune checkpoint blockade\nL6: Reference URL: https://www.nature.com/articles/s41586-025-09006-8\nL7: \nL8: ## Objective\nL9: Read the report and produce all required JSON outputs that satisfy their schemas.\nL10: \nL11: ## Inputs On Disk\nL12: - Report: `input/report.md`\nL13: - Schemas: in `schemas/`\nL14: \nL15: ## Required Outputs\nL16: - `output/study_overview.json` (schema: `schemas/study_overview.schema.json`)\nL17: - `output/quantitative_findings.json` (schema: `schemas/quantitative_findings.schema.json`)\nL18: - `output/claim_audit.json` (schema: `schemas/claim_audit.schema.json`)\nL19: - `output/public_summary.json` (schema: `schemas/public_summary.schema.json`)\nL20: \nL21: ## Constraints\nL22: - Do not invent source facts; derive calculations only from values in the report.\nL23: - Use line refs as `L<number>` where required.\nL24: - Where quotes are required, copy exact report snippets.\nL25: - For calculation outputs, line_refs must include every report line used for equations, constants, and numeric substitutions.\nL26: - Use relative paths only.\nL27: - Never use absolute paths.\nL28: - Never use `..` in paths.\nL29: - Write valid JSON only.\nL30: \nL31: ## Completion\nL32: Respond with a checklist of written output files.\nL33: After the checklist, stop. Do not call more tools.",
            "callId": "call_VlzfcIrnqyy90jMWEGBjCxYQ"
          }
        ],
        "usage": {
          "promptTokens": 571,
          "cachedTokens": 0,
          "responseTokens": 30,
          "thinkingTokens": 29,
          "totalTokens": 630
        },
        "costUsd": 0.00182525
      },
      {
        "step": 2,
        "modelVersion": "chatgpt-gpt-5.2-2025-12-11",
        "thoughts": "**Reading reports and schemas**\n\nI need to review the report and schemas for Phase 1. My plan is to read both documents and then draft something based on my findings. I'll use some tools to help me read the files more efficiently. First, I should inspect the directory to see what's available. I want to make sure I have everything I need before diving into the details to get this right!",
        "toolCalls": [
          {
            "toolName": "list_directory",
            "input": {
              "dir_path": ".",
              "ignore": null,
              "file_filtering_options": {
                "respect_git_ignore": null,
                "respect_gemini_ignore": null
              }
            },
            "output": "input/\noutput/\nschemas/\nTASK.md",
            "callId": "call_YdJ2GmNzRFrizXViI83HaS5W"
          }
        ],
        "usage": {
          "promptTokens": 1018,
          "cachedTokens": 0,
          "responseTokens": 44,
          "thinkingTokens": 30,
          "totalTokens": 1092
        },
        "costUsd": 0.0028174999999999997
      },
      {
        "step": 3,
        "modelVersion": "chatgpt-gpt-5.2-2025-12-11",
        "toolCalls": [
          {
            "toolName": "read_file",
            "input": {
              "file_path": "input/report.md",
              "offset": 0,
              "limit": 2000
            },
            "output": "L1: # Structured Paper Report: Tumor Sensitization by mRNA Vaccination\nL2: \nL3: ## Citation\nL4: - Title: SARS-CoV-2 mRNA vaccines sensitize tumours to immune checkpoint blockade\nL5: - Journal: Nature\nL6: - Year: 2025\nL7: - DOI: 10.1038/s41586-025-09006-8\nL8: - Source URL: https://www.nature.com/articles/s41586-025-09006-8\nL9: \nL10: ## One-Paragraph Context\nL11: Immune checkpoint inhibitors (ICIs) can produce durable responses in some cancers, but many tumors remain non-responsive due to weak antigen presentation or poor immune priming. The paper investigates whether intratumoral delivery of an mRNA vaccine can create an interferon-rich inflammatory state that improves sensitivity to anti-PD-L1 therapy.\nL12: \nL13: ## Study Design Snapshot\nL14: - Preclinical arm: multiple murine tumor models with intratumoral mRNA vaccine and anti-PD-L1 combinations.\nL15: - Translational arm: a retrospective cohort of metastatic patients receiving ICI treatment, compared by prior SARS-CoV-2 mRNA vaccination status.\nL16: - Mechanistic probes: immunopeptidomics, transcriptomics, and perturbation controls (including IFNAR1 blockade and non-mRNA particle controls).\nL17: \nL18: ## Cohorts and Scenarios\nL19: 1. Mouse efficacy cohort (combination therapy): 78 tumor-bearing mice pooled across repeat experiments.\nL20: 2. Mouse control cohort (vaccine only, ICI only, and vehicle): 84 tumor-bearing mice pooled across matched controls.\nL21: 3. Human retrospective metastatic cohort: 130 patients total.\nL22: 4. Human vaccinated subgroup: 43 patients.\nL23: 5. Human unvaccinated subgroup: 87 patients.\nL24: \nL25: ## Quantitative Findings\nL26: | Metric | Vaccine/Combination Arm | Comparator | Interpretation |\nL27: |---|---:|---:|---|\nL28: | Fraction of tumor proteins represented in immunopeptidome | 62.3% | 37.3% | Broader antigen display after intratumoral mRNA vaccination |\nL29: | Fraction of proteins represented in MHC-I peptidome | 40.6% | 20.6% | Strong expansion of MHC-I-presented landscape |\nL30: | Retrospective human survival comparison p-value | p=0.01 | N/A | Vaccinated subgroup had improved survival under ICI treatment |\nL31: | Type I interferon response score (normalized units) | 3.1 | 1.0 | Marked induction after mRNA vaccination in tumors |\nL32: | PD-L1 expression fold-change in tumor tissue | 2.4x | 1.0x | Checkpoint axis became more targetable |\nL33: | Intratumoral CD8+ T-cell density fold-change | 1.8x | 1.0x | Increased immune infiltration with combination therapy |\nL34: \nL35: ## Controls and Null/Conditional Results\nL36: - Vaccine-only treatment did not produce durable tumor control in non-immunogenic models.\nL37: - ICI-only treatment had limited activity in low-immunogenic baseline settings.\nL38: - Lipid particle controls lacking mRNA did not reproduce the sensitization effect.\nL39: - Blocking type I interferon signaling with anti-IFNAR1 eliminated the observed sensitization benefit.\nL40: \nL41: ## Mechanistic Chain Proposed by Authors\nL42: 1. Intratumoral mRNA vaccination triggers local innate sensing and type I interferon signaling.\nL43: 2. Interferon-associated antigen processing and presentation pathways increase.\nL44: 3. A broader peptide repertoire appears on MHC-I, improving tumor visibility to T cells.\nL45: 4. PD-L1 pathway activity also increases, creating a rationale for combining with checkpoint blockade.\nL46: 5. Combined intervention improves tumor control in mice and aligns with better outcomes in the retrospective human cohort.\nL47: \nL48: ## Caveats and Threats to Validity\nL49: - The human analysis is retrospective and non-randomized; residual confounding is likely.\nL50: - Vaccination timing relative to ICI initiation varied across patients.\nL51: - Tumor-type mix and treatment-history heterogeneity limit direct causal interpretation.\nL52: - Mouse model effects may not map one-to-one to all human tumors.\nL53: - Some mechanistic readouts were strongest in specific model systems rather than uniformly across all tested settings.\nL54: \nL55: ## Practical Takeaway\nL56: The study supports a biologically coherent hypothesis that intratumoral mRNA vaccination can prime tumors for stronger ICI responses, but prospective randomized studies are required before clinical protocol changes are justified.",
            "callId": "call_eVReR4EOiE6DMatR23X1Emas"
          },
          {
            "toolName": "list_directory",
            "input": {
              "dir_path": "schemas",
              "ignore": null,
              "file_filtering_options": {
                "respect_git_ignore": null,
                "respect_gemini_ignore": null
              }
            },
            "output": "claim_audit.schema.json\npublic_summary.schema.json\nquantitative_findings.schema.json\nstudy_overview.schema.json",
            "callId": "call_ykN7vBj5hrTOrmqbNgp9WZR1"
          }
        ],
        "usage": {
          "promptTokens": 1076,
          "cachedTokens": 0,
          "responseTokens": 85,
          "thinkingTokens": 0,
          "totalTokens": 1161
        },
        "costUsd": 0.003073
      },
      {
        "step": 4,
        "modelVersion": "chatgpt-gpt-5.2-2025-12-11",
        "toolCalls": [
          {
            "toolName": "read_file",
            "input": {
              "file_path": "schemas/study_overview.schema.json",
              "offset": 0,
              "limit": 400
            },
            "output": "L1: {\nL2:   \"$schema\": \"http://json-schema.org/draft-07/schema#\",\nL3:   \"title\": \"schemas-study_overview\",\nL4:   \"type\": \"object\",\nL5:   \"properties\": {\nL6:     \"paper\": {\nL7:       \"type\": \"object\",\nL8:       \"properties\": {\nL9:         \"title\": {\nL10:           \"type\": \"string\",\nL11:           \"minLength\": 10\nL12:         },\nL13:         \"doi\": {\nL14:           \"type\": \"string\",\nL15:           \"pattern\": \"^10\\\\.\"\nL16:         },\nL17:         \"publication_year\": {\nL18:           \"type\": \"integer\",\nL19:           \"minimum\": 1900,\nL20:           \"maximum\": 2100\nL21:         },\nL22:         \"domain\": {\nL23:           \"type\": \"string\",\nL24:           \"enum\": [\nL25:             \"oncology-immunology\",\nL26:             \"exoplanet-atmospheres\",\nL27:             \"climate-science\",\nL28:             \"neuroscience\",\nL29:             \"other\"\nL30:           ]\nL31:         },\nL32:         \"study_type\": {\nL33:           \"type\": \"string\",\nL34:           \"enum\": [\nL35:             \"preclinical+retrospective\",\nL36:             \"observational-astronomy\",\nL37:             \"randomized-trial\",\nL38:             \"simulation\",\nL39:             \"mixed\"\nL40:           ]\nL41:         }\nL42:       },\nL43:       \"required\": [\nL44:         \"title\",\nL45:         \"doi\",\nL46:         \"publication_year\",\nL47:         \"domain\",\nL48:         \"study_type\"\nL49:       ],\nL50:       \"additionalProperties\": false\nL51:     },\nL52:     \"core_question\": {\nL53:       \"type\": \"string\",\nL54:       \"minLength\": 20\nL55:     },\nL56:     \"datasets_or_cohorts\": {\nL57:       \"type\": \"array\",\nL58:       \"items\": {\nL59:         \"type\": \"object\",\nL60:         \"properties\": {\nL61:           \"id\": {\nL62:             \"type\": \"string\",\nL63:             \"pattern\": \"^[a-z0-9-]+$\"\nL64:           },\nL65:           \"label\": {\nL66:             \"type\": \"string\",\nL67:             \"minLength\": 3\nL68:           },\nL69:           \"sample_size_or_observations\": {\nL70:             \"type\": \"string\",\nL71:             \"minLength\": 1\nL72:           },\nL73:           \"description\": {\nL74:             \"type\": \"string\",\nL75:             \"minLength\": 20\nL76:           }\nL77:         },\nL78:         \"required\": [\nL79:           \"id\",\nL80:           \"label\",\nL81:           \"sample_size_or_observations\",\nL82:           \"description\"\nL83:         ],\nL84:         \"additionalProperties\": false\nL85:       },\nL86:       \"minItems\": 2,\nL87:       \"maxItems\": 8\nL88:     },\nL89:     \"major_limitations\": {\nL90:       \"type\": \"array\",\nL91:       \"items\": {\nL92:         \"type\": \"string\",\nL93:         \"minLength\": 12\nL94:       },\nL95:       \"minItems\": 3,\nL96:       \"maxItems\": 8\nL97:     }\nL98:   },\nL99:   \"required\": [\nL100:     \"paper\",\nL101:     \"core_question\",\nL102:     \"datasets_or_cohorts\",\nL103:     \"major_limitations\"\nL104:   ],\nL105:   \"additionalProperties\": false\nL106: }",
            "callId": "call_RrNC1QLRRNqIY2u7T0yQPRVd"
          },
          {
            "toolName": "read_file",
            "input": {
              "file_path": "schemas/quantitative_findings.schema.json",
              "offset": 0,
              "limit": 400
            },
            "output": "L1: {\nL2:   \"$schema\": \"http://json-schema.org/draft-07/schema#\",\nL3:   \"title\": \"schemas-quantitative_findings\",\nL4:   \"type\": \"object\",\nL5:   \"properties\": {\nL6:     \"findings\": {\nL7:       \"type\": \"array\",\nL8:       \"items\": {\nL9:         \"type\": \"object\",\nL10:         \"properties\": {\nL11:           \"id\": {\nL12:             \"type\": \"string\",\nL13:             \"pattern\": \"^Q[0-9]{2}$\"\nL14:           },\nL15:           \"metric\": {\nL16:             \"type\": \"string\",\nL17:             \"minLength\": 6\nL18:           },\nL19:           \"value\": {\nL20:             \"type\": \"string\",\nL21:             \"minLength\": 1\nL22:           },\nL23:           \"comparator_or_baseline\": {\nL24:             \"type\": \"string\",\nL25:             \"minLength\": 1\nL26:           },\nL27:           \"interpretation\": {\nL28:             \"type\": \"string\",\nL29:             \"minLength\": 12\nL30:           },\nL31:           \"evidence_line_refs\": {\nL32:             \"type\": \"array\",\nL33:             \"items\": {\nL34:               \"type\": \"string\",\nL35:               \"pattern\": \"^L[1-9]\\\\d*$\"\nL36:             },\nL37:             \"minItems\": 1,\nL38:             \"maxItems\": 3\nL39:           }\nL40:         },\nL41:         \"required\": [\nL42:           \"id\",\nL43:           \"metric\",\nL44:           \"value\",\nL45:           \"comparator_or_baseline\",\nL46:           \"interpretation\",\nL47:           \"evidence_line_refs\"\nL48:         ],\nL49:         \"additionalProperties\": false\nL50:       },\nL51:       \"minItems\": 5,\nL52:       \"maxItems\": 14\nL53:     },\nL54:     \"controls_or_null_results\": {\nL55:       \"type\": \"array\",\nL56:       \"items\": {\nL57:         \"type\": \"object\",\nL58:         \"properties\": {\nL59:           \"statement\": {\nL60:             \"type\": \"string\",\nL61:             \"minLength\": 10\nL62:           },\nL63:           \"evidence_line_ref\": {\nL64:             \"$ref\": \"#/definitions/schemas-quantitative_findings/properties/findings/items/properties/evidence_line_refs/items\"\nL65:           }\nL66:         },\nL67:         \"required\": [\nL68:           \"statement\",\nL69:           \"evidence_line_ref\"\nL70:         ],\nL71:         \"additionalProperties\": false\nL72:       },\nL73:       \"minItems\": 2,\nL74:       \"maxItems\": 10\nL75:     }\nL76:   },\nL77:   \"required\": [\nL78:     \"findings\",\nL79:     \"controls_or_null_results\"\nL80:   ],\nL81:   \"additionalProperties\": false\nL82: }",
            "callId": "call_LRtn05eaDIxTv1CKfi3DakRA"
          },
          {
            "toolName": "read_file",
            "input": {
              "file_path": "schemas/claim_audit.schema.json",
              "offset": 0,
              "limit": 400
            },
            "output": "L1: {\nL2:   \"$schema\": \"http://json-schema.org/draft-07/schema#\",\nL3:   \"title\": \"schemas-claim_audit\",\nL4:   \"type\": \"object\",\nL5:   \"properties\": {\nL6:     \"claims\": {\nL7:       \"type\": \"array\",\nL8:       \"items\": {\nL9:         \"type\": \"object\",\nL10:         \"properties\": {\nL11:           \"claim_id\": {\nL12:             \"type\": \"string\",\nL13:             \"pattern\": \"^C[0-9]{2}$\"\nL14:           },\nL15:           \"claim\": {\nL16:             \"type\": \"string\",\nL17:             \"minLength\": 20\nL18:           },\nL19:           \"strength\": {\nL20:             \"type\": \"string\",\nL21:             \"enum\": [\nL22:               \"strong\",\nL23:               \"moderate\",\nL24:               \"tentative\"\nL25:             ]\nL26:           },\nL27:           \"evidence\": {\nL28:             \"type\": \"array\",\nL29:             \"items\": {\nL30:               \"type\": \"object\",\nL31:               \"properties\": {\nL32:                 \"quote\": {\nL33:                   \"type\": \"string\",\nL34:                   \"minLength\": 10\nL35:                 },\nL36:                 \"line_ref\": {\nL37:                   \"type\": \"string\",\nL38:                   \"pattern\": \"^L[1-9]\\\\d*$\"\nL39:                 }\nL40:               },\nL41:               \"required\": [\nL42:                 \"quote\",\nL43:                 \"line_ref\"\nL44:               ],\nL45:               \"additionalProperties\": false\nL46:             },\nL47:             \"minItems\": 2,\nL48:             \"maxItems\": 3\nL49:           },\nL50:           \"caveat\": {\nL51:             \"type\": \"string\",\nL52:             \"minLength\": 20\nL53:           }\nL54:         },\nL55:         \"required\": [\nL56:           \"claim_id\",\nL57:           \"claim\",\nL58:           \"strength\",\nL59:           \"evidence\",\nL60:           \"caveat\"\nL61:         ],\nL62:         \"additionalProperties\": false\nL63:       },\nL64:       \"minItems\": 4,\nL65:       \"maxItems\": 10\nL66:     }\nL67:   },\nL68:   \"required\": [\nL69:     \"claims\"\nL70:   ],\nL71:   \"additionalProperties\": false\nL72: }",
            "callId": "call_3HfpCQWdTFy6h5c6onaaLcW5"
          },
          {
            "toolName": "read_file",
            "input": {
              "file_path": "schemas/public_summary.schema.json",
              "offset": 0,
              "limit": 400
            },
            "output": "L1: {\nL2:   \"$schema\": \"http://json-schema.org/draft-07/schema#\",\nL3:   \"title\": \"schemas-public_summary\",\nL4:   \"type\": \"object\",\nL5:   \"properties\": {\nL6:     \"headline\": {\nL7:       \"type\": \"string\",\nL8:       \"minLength\": 20,\nL9:       \"maxLength\": 120\nL10:     },\nL11:     \"plain_language_summary\": {\nL12:       \"type\": \"string\",\nL13:       \"minLength\": 180,\nL14:       \"maxLength\": 1200\nL15:     },\nL16:     \"what_is_new\": {\nL17:       \"type\": \"array\",\nL18:       \"items\": {\nL19:         \"type\": \"string\",\nL20:         \"minLength\": 20\nL21:       },\nL22:       \"minItems\": 3,\nL23:       \"maxItems\": 3\nL24:     },\nL25:     \"why_caution_is_needed\": {\nL26:       \"type\": \"array\",\nL27:       \"items\": {\nL28:         \"type\": \"string\",\nL29:         \"minLength\": 20\nL30:       },\nL31:       \"minItems\": 3,\nL32:       \"maxItems\": 5\nL33:     },\nL34:     \"glossary\": {\nL35:       \"type\": \"array\",\nL36:       \"items\": {\nL37:         \"type\": \"object\",\nL38:         \"properties\": {\nL39:           \"term\": {\nL40:             \"type\": \"string\",\nL41:             \"minLength\": 2\nL42:           },\nL43:           \"definition\": {\nL44:             \"type\": \"string\",\nL45:             \"minLength\": 20,\nL46:             \"maxLength\": 220\nL47:           }\nL48:         },\nL49:         \"required\": [\nL50:           \"term\",\nL51:           \"definition\"\nL52:         ],\nL53:         \"additionalProperties\": false\nL54:       },\nL55:       \"minItems\": 4,\nL56:       \"maxItems\": 8\nL57:     },\nL58:     \"open_questions\": {\nL59:       \"type\": \"array\",\nL60:       \"items\": {\nL61:         \"type\": \"string\",\nL62:         \"minLength\": 20\nL63:       },\nL64:       \"minItems\": 3,\nL65:       \"maxItems\": 6\nL66:     }\nL67:   },\nL68:   \"required\": [\nL69:     \"headline\",\nL70:     \"plain_language_summary\",\nL71:     \"what_is_new\",\nL72:     \"why_caution_is_needed\",\nL73:     \"glossary\",\nL74:     \"open_questions\"\nL75:   ],\nL76:   \"additionalProperties\": false\nL77: }",
            "callId": "call_YKa3L2iSr8drReLdA0ReDf5v"
          }
        ],
        "usage": {
          "promptTokens": 2251,
          "cachedTokens": 0,
          "responseTokens": 135,
          "thinkingTokens": 0,
          "totalTokens": 2386
        },
        "costUsd": 0.00582925
      },
      {
        "step": 5,
        "modelVersion": "chatgpt-gpt-5.2-2025-12-11",
        "thoughts": "**Analyzing statistical results**\n\nI'm looking at the p-value row where \"p=0.01\" meets the minimum length requirement. I see the evidence from L30 supports this. The Type I IFN score is 3.1 compared to 1.0 in L31, and there's a PD-L1 fold change from 2.4x to 1.0x in L32. CD8 density changes from 1.8x to 1.0x in L33, and the MHC-I peptidome fraction shifts from 40.6% to 20.6% in L29. Wait, I need to total these!**Extracting evidence quotes**\n\nI need to gather exact snippets from the report for each evidence array, ensuring the quote length is at least 10 words. For C01, the claim states that \"intratumoral mRNA vaccination is proposed to trigger local innate sensing and type I interferon signaling.\" I can use lines L42 and L43 for quotes: the first being about mRNA vaccination triggering signaling and the second on associated pathways. I must also include a caveat about how mechanistic readouts vary across systems. I'll reference line 53 while making sure everything is accurate.**Formulating claims and evidence**\n\nI’m focusing on the C02 claim that \"intratumoral mRNA vaccination broadened antigen display,\" showing 62.3% versus 37.3% of tumor proteins represented. I’ll pull quotes from L28 and L44, noting the strength of the evidence is strong. There’s a caveat mentioning that mouse model effects might not directly apply to all human tumors, with a reference to L52. \n\nFor C03, the claim states mRNA vaccination increased MHC-I peptidome coverage from 40.6% to 20.6%, and I’ll use evidence from L29 and L44 or L43. The strength here is also strong, with a similar caveat about applicability. C04 involves increased PD-L1 expression post-vaccination, backed by evidence from L32 and L45 and labeled as moderate strength. I'm thinking about using line 56 about needing prospective randomized studies for the caveat, mentioning that these are necessary.**Structuring claims and evidence**\n\nI'm working on the C05 claim that states in a retrospective cohort of metastatic patients receiving ICI, prior SARS-CoV-2 mRNA vaccination is linked to improved survival (p=0.01). I’ll use quotes from L15 about the cohort comparison by vaccination status and L30, which discusses the survival comparison's p-value. The strength of this claim seems tentative. \n\nFor the caveat, I'll mention confounding factors and that this is a non-randomized study from L49-L51. I’m also considering adding the claim about IFNAR1 blockade eliminating this benefit as C06. Since we’ll have six claims total, that sounds good!**Finalizing claims and summaries**\n\nI need to cap the number of claims at six, which means I'll label them as C01 to C06. For C06, the claim is about blocking type I interferon signaling with anti-IFNAR1, eliminating the sensitization benefit. I’ll pull evidence from L39 and L42 with a strong strength rating. The caveat will highlight limitations relating to mouse model translations from L52.\n\nIn the public summary, I want to focus on how intratumoral mRNA vaccination may prime tumors for anti-PD-L1, connecting vaccination status to better ICI outcomes, keeping it concise. I need to create a plain language summary discussing mRNA vaccines, tumor injections in mice, and retrospective human cohorts, while also explaining the need for caution in retrospective studies.\n\nI’m also considering what’s new, definitions for terms like immune checkpoint inhibitor, and open questions to include. Now, I’ll move into composing these segments.",
        "toolCalls": [
          {
            "toolName": "write_file",
            "input": {
              "file_path": "output/study_overview.json",
              "content": "{\n  \"paper\": {\n    \"title\": \"SARS-CoV-2 mRNA vaccines sensitize tumours to immune checkpoint blockade\",\n    \"doi\": \"10.1038/s41586-025-09006-8\",\n    \"publication_year\": 2025,\n    \"domain\": \"oncology-immunology\",\n    \"study_type\": \"preclinical+retrospective\"\n  },\n  \"core_question\": \"Can intratumoral delivery of an mRNA vaccine induce an interferon-rich tumor state that improves sensitivity to anti-PD-L1 immune checkpoint blockade?\",\n  \"datasets_or_cohorts\": [\n    {\n      \"id\": \"mouse-efficacy-combo\",\n      \"label\": \"Mouse efficacy cohort (combination therapy)\",\n      \"sample_size_or_observations\": \"78 tumor-bearing mice\",\n      \"description\": \"Pooled murine tumor-model experiments testing intratumoral mRNA vaccination in combination with anti-PD-L1 treatment for tumor control.\"\n    },\n    {\n      \"id\": \"mouse-controls\",\n      \"label\": \"Mouse control cohort (vaccine only, ICI only, vehicle)\",\n      \"sample_size_or_observations\": \"84 tumor-bearing mice\",\n      \"description\": \"Matched murine control arms used to contextualize combination effects, including vaccine-only, ICI-only, and vehicle conditions.\"\n    },\n    {\n      \"id\": \"human-retrospective-metastatic\",\n      \"label\": \"Human retrospective metastatic cohort\",\n      \"sample_size_or_observations\": \"130 patients\",\n      \"description\": \"Retrospective analysis of metastatic patients receiving immune checkpoint inhibitor therapy, stratified by prior SARS-CoV-2 mRNA vaccination status.\"\n    },\n    {\n      \"id\": \"human-vaccinated\",\n      \"label\": \"Human vaccinated subgroup\",\n      \"sample_size_or_observations\": \"43 patients\",\n      \"description\": \"Subset of the retrospective metastatic cohort with documented prior SARS-CoV-2 mRNA vaccination exposure before or around ICI treatment.\"\n    },\n    {\n      \"id\": \"human-unvaccinated\",\n      \"label\": \"Human unvaccinated subgroup\",\n      \"sample_size_or_observations\": \"87 patients\",\n      \"description\": \"Subset of the retrospective metastatic cohort without prior SARS-CoV-2 mRNA vaccination, used as the comparison group for survival analyses.\"\n    }\n  ],\n  \"major_limitations\": [\n    \"Human analysis was retrospective and non-randomized, so residual confounding is likely.\",\n    \"Vaccination timing relative to ICI initiation varied across patients.\",\n    \"Tumor-type mix and treatment-history heterogeneity limit causal interpretation.\",\n    \"Mouse model effects may not map one-to-one to all human tumors.\",\n    \"Some mechanistic readouts were strongest in specific model systems rather than uniformly across all tested settings.\"\n  ]\n}\n"
            },
            "output": "Successfully wrote file: output/study_overview.json",
            "callId": "call_NnJ85z8cW9fLcWsGJQCw2DAi"
          },
          {
            "toolName": "write_file",
            "input": {
              "file_path": "output/quantitative_findings.json",
              "content": "{\n  \"findings\": [\n    {\n      \"id\": \"Q01\",\n      \"metric\": \"Fraction of tumor proteins represented in immunopeptidome\",\n      \"value\": \"62.3%\",\n      \"comparator_or_baseline\": \"37.3%\",\n      \"interpretation\": \"Broader antigen display after intratumoral mRNA vaccination.\",\n      \"evidence_line_refs\": [\n        \"L28\"\n      ]\n    },\n    {\n      \"id\": \"Q02\",\n      \"metric\": \"Fraction of proteins represented in MHC-I peptidome\",\n      \"value\": \"40.6%\",\n      \"comparator_or_baseline\": \"20.6%\",\n      \"interpretation\": \"Strong expansion of the MHC-I-presented landscape.\",\n      \"evidence_line_refs\": [\n        \"L29\"\n      ]\n    },\n    {\n      \"id\": \"Q03\",\n      \"metric\": \"Retrospective human survival comparison p-value\",\n      \"value\": \"p=0.01\",\n      \"comparator_or_baseline\": \"N/A\",\n      \"interpretation\": \"Vaccinated subgroup had improved survival under ICI treatment.\",\n      \"evidence_line_refs\": [\n        \"L30\"\n      ]\n    },\n    {\n      \"id\": \"Q04\",\n      \"metric\": \"Type I interferon response score (normalized units)\",\n      \"value\": \"3.1\",\n      \"comparator_or_baseline\": \"1.0\",\n      \"interpretation\": \"Marked induction of type I interferon response after mRNA vaccination in tumors.\",\n      \"evidence_line_refs\": [\n        \"L31\"\n      ]\n    },\n    {\n      \"id\": \"Q05\",\n      \"metric\": \"PD-L1 expression fold-change in tumor tissue\",\n      \"value\": \"2.4x\",\n      \"comparator_or_baseline\": \"1.0x\",\n      \"interpretation\": \"Checkpoint axis became more targetable after vaccination.\",\n      \"evidence_line_refs\": [\n        \"L32\"\n      ]\n    },\n    {\n      \"id\": \"Q06\",\n      \"metric\": \"Intratumoral CD8+ T-cell density fold-change\",\n      \"value\": \"1.8x\",\n      \"comparator_or_baseline\": \"1.0x\",\n      \"interpretation\": \"Increased immune infiltration with combination therapy.\",\n      \"evidence_line_refs\": [\n        \"L33\"\n      ]\n    }\n  ],\n  \"controls_or_null_results\": [\n    {\n      \"statement\": \"Vaccine-only treatment did not produce durable tumor control in non-immunogenic models.\",\n      \"evidence_line_ref\": \"L36\"\n    },\n    {\n      \"statement\": \"ICI-only treatment had limited activity in low-immunogenic baseline settings.\",\n      \"evidence_line_ref\": \"L37\"\n    },\n    {\n      \"statement\": \"Lipid particle controls lacking mRNA did not reproduce the sensitization effect.\",\n      \"evidence_line_ref\": \"L38\"\n    },\n    {\n      \"statement\": \"Blocking type I interferon signaling with anti-IFNAR1 eliminated the observed sensitization benefit.\",\n      \"evidence_line_ref\": \"L39\"\n    }\n  ]\n}\n"
            },
            "output": "Successfully wrote file: output/quantitative_findings.json",
            "callId": "call_zH8vNM9LgG4TtCPBARqtYIuj"
          },
          {
            "toolName": "write_file",
            "input": {
              "file_path": "output/claim_audit.json",
              "content": "{\n  \"claims\": [\n    {\n      \"claim_id\": \"C01\",\n      \"claim\": \"Intratumoral mRNA vaccination is proposed to trigger type I interferon signaling and increase antigen processing/presentation in the tumor.\",\n      \"strength\": \"moderate\",\n      \"evidence\": [\n        {\n          \"quote\": \"Intratumoral mRNA vaccination triggers local innate sensing and type I interferon signaling.\",\n          \"line_ref\": \"L42\"\n        },\n        {\n          \"quote\": \"Interferon-associated antigen processing and presentation pathways increase.\",\n          \"line_ref\": \"L43\"\n        }\n      ],\n      \"caveat\": \"This is presented as a proposed mechanistic chain, and the report notes that some mechanistic readouts were strongest in specific model systems rather than uniformly across all tested settings.\"\n    },\n    {\n      \"claim_id\": \"C02\",\n      \"claim\": \"Intratumoral mRNA vaccination broadened tumor antigen display in immunopeptidomics (62.3% versus 37.3% of tumor proteins represented).\",\n      \"strength\": \"strong\",\n      \"evidence\": [\n        {\n          \"quote\": \"Fraction of tumor proteins represented in immunopeptidome | 62.3% | 37.3% | Broader antigen display after intratumoral mRNA vaccination\",\n          \"line_ref\": \"L28\"\n        },\n        {\n          \"quote\": \"A broader peptide repertoire appears on MHC-I, improving tumor visibility to T cells.\",\n          \"line_ref\": \"L44\"\n        }\n      ],\n      \"caveat\": \"The report cautions that mouse model effects may not map one-to-one to all human tumors, so the magnitude of peptide-display changes may differ across settings.\"\n    },\n    {\n      \"claim_id\": \"C03\",\n      \"claim\": \"Intratumoral mRNA vaccination expanded the fraction of proteins represented in the MHC-I peptidome (40.6% versus 20.6%).\",\n      \"strength\": \"strong\",\n      \"evidence\": [\n        {\n          \"quote\": \"Fraction of proteins represented in MHC-I peptidome | 40.6% | 20.6% | Strong expansion of MHC-I-presented landscape\",\n          \"line_ref\": \"L29\"\n        },\n        {\n          \"quote\": \"A broader peptide repertoire appears on MHC-I, improving tumor visibility to T cells.\",\n          \"line_ref\": \"L44\"\n        }\n      ],\n      \"caveat\": \"These measurements are drawn from preclinical tumor-model experiments, and the report notes that effects observed in mice may not translate directly across all human tumors.\"\n    },\n    {\n      \"claim_id\": \"C04\",\n      \"claim\": \"mRNA vaccination increased PD-L1 expression in tumor tissue (2.4×), supporting a rationale for combining vaccination with checkpoint blockade.\",\n      \"strength\": \"moderate\",\n      \"evidence\": [\n        {\n          \"quote\": \"PD-L1 expression fold-change in tumor tissue | 2.4x | 1.0x | Checkpoint axis became more targetable\",\n          \"line_ref\": \"L32\"\n        },\n        {\n          \"quote\": \"PD-L1 pathway activity also increases, creating a rationale for combining with checkpoint blockade.\",\n          \"line_ref\": \"L45\"\n        }\n      ],\n      \"caveat\": \"An increase in PD-L1 does not by itself prove improved clinical benefit, and the report emphasizes that prospective randomized studies are required before clinical protocol changes are justified.\"\n    },\n    {\n      \"claim_id\": \"C05\",\n      \"claim\": \"In a retrospective metastatic patient cohort receiving ICI therapy, prior SARS-CoV-2 mRNA vaccination was associated with improved survival (p=0.01).\",\n      \"strength\": \"tentative\",\n      \"evidence\": [\n        {\n          \"quote\": \"Translational arm: a retrospective cohort of metastatic patients receiving ICI treatment, compared by prior SARS-CoV-2 mRNA vaccination status.\",\n          \"line_ref\": \"L15\"\n        },\n        {\n          \"quote\": \"Retrospective human survival comparison p-value | p=0.01 | N/A | Vaccinated subgroup had improved survival under ICI treatment\",\n          \"line_ref\": \"L30\"\n        },\n        {\n          \"quote\": \"The human analysis is retrospective and non-randomized; residual confounding is likely.\",\n          \"line_ref\": \"L49\"\n        }\n      ],\n      \"caveat\": \"Because the analysis is retrospective with varied vaccination timing and heterogeneous tumor types/treatment histories, the observed association cannot be interpreted as causal.\"\n    },\n    {\n      \"claim_id\": \"C06\",\n      \"claim\": \"Blocking type I interferon signaling with anti-IFNAR1 eliminated the sensitization benefit attributed to intratumoral mRNA vaccination.\",\n      \"strength\": \"strong\",\n      \"evidence\": [\n        {\n          \"quote\": \"Blocking type I interferon signaling with anti-IFNAR1 eliminated the observed sensitization benefit.\",\n          \"line_ref\": \"L39\"\n        },\n        {\n          \"quote\": \"Intratumoral mRNA vaccination triggers local innate sensing and type I interferon signaling.\",\n          \"line_ref\": \"L42\"\n        }\n      ],\n      \"caveat\": \"This perturbation result is reported for the preclinical system, and the report notes that mouse model effects may not map one-to-one to all human tumors.\"\n    }\n  ]\n}\n"
            },
            "output": "Successfully wrote file: output/claim_audit.json",
            "callId": "call_bl0BFh6SaH639Wqs1bYuW1Bc"
          },
          {
            "toolName": "write_file",
            "input": {
              "file_path": "output/public_summary.json",
              "content": "{\n  \"headline\": \"Intratumoral mRNA vaccination may prime tumors to respond better to anti-PD-L1 therapy\",\n  \"plain_language_summary\": \"Immune checkpoint inhibitors (ICIs) can work well for some people with cancer, but many tumors do not respond because the immune system is not strongly activated against them. This study tested whether delivering an mRNA vaccine directly into a tumor can create a local, interferon-driven inflammatory environment that makes tumors easier for immune cells to recognize and attack. In mouse tumor models, the authors report broader presentation of tumor peptides on MHC-I and increases in signals linked to immune activation, alongside increased PD-L1 pathway activity that could make anti-PD-L1 therapy more effective. The paper also includes a retrospective (non-randomized) analysis of 130 metastatic patients treated with ICIs, where prior SARS-CoV-2 mRNA vaccination was associated with improved survival (p=0.01). Because the human data are observational and vaccination timing and patient histories vary, the results support a hypothesis but do not prove that vaccination causes better outcomes; prospective randomized trials would be needed before changing clinical practice.\",\n  \"what_is_new\": [\n    \"Tests intratumoral mRNA vaccination as a way to induce an interferon-rich tumor microenvironment.\",\n    \"Reports broader tumor peptide display on MHC-I after intratumoral mRNA vaccination in mice.\",\n    \"Links prior SARS-CoV-2 mRNA vaccination to better survival under ICI in a retrospective cohort.\"\n  ],\n  \"why_caution_is_needed\": [\n    \"The human cohort analysis is retrospective and non-randomized, so confounding could explain the association.\",\n    \"Vaccination timing relative to starting checkpoint therapy varied across patients, complicating interpretation.\",\n    \"Different tumor types and prior treatments were mixed together, limiting direct causal conclusions.\",\n    \"Mouse tumor-model findings may not translate directly to all human cancers or clinical protocols.\"\n  ],\n  \"glossary\": [\n    {\n      \"term\": \"Immune checkpoint inhibitor (ICI)\",\n      \"definition\": \"A cancer immunotherapy drug that releases brakes on T cells (for example, anti-PD-1 or anti-PD-L1) to help them attack tumors.\"\n    },\n    {\n      \"term\": \"PD-L1\",\n      \"definition\": \"A protein that can suppress T-cell activity by engaging PD-1; higher PD-L1 activity can make tumors targets for anti-PD-L1 drugs.\"\n    },\n    {\n      \"term\": \"Type I interferon\",\n      \"definition\": \"A family of innate immune signals that can drive inflammation and upregulate pathways involved in antigen processing and presentation.\"\n    },\n    {\n      \"term\": \"MHC-I\",\n      \"definition\": \"A cell-surface molecule that displays short peptide fragments to CD8+ T cells, helping the immune system recognize abnormal cells.\"\n    },\n    {\n      \"term\": \"Immunopeptidome\",\n      \"definition\": \"The set of peptides displayed on MHC molecules in a tissue; changes in the immunopeptidome can reflect altered antigen presentation.\"\n    }\n  ],\n  \"open_questions\": [\n    \"Would a prospective randomized trial confirm a causal benefit of vaccination-associated priming for ICI responses?\",\n    \"Which tumor types and clinical contexts are most likely to show meaningful sensitization to checkpoint blockade?\",\n    \"What dosing, timing, and delivery method for intratumoral mRNA would be feasible and safe in humans?\",\n    \"How durable are the interferon and antigen-presentation changes, and do they correlate with long-term tumor control?\"\n  ]\n}\n"
            },
            "output": "Successfully wrote file: output/public_summary.json",
            "callId": "call_WwpcyWkQmNcPrTQ8CXG0eN3J"
          }
        ],
        "usage": {
          "promptTokens": 5333,
          "cachedTokens": 1408,
          "responseTokens": 3684,
          "thinkingTokens": 2249,
          "totalTokens": 11266
        },
        "costUsd": 0.09017715
      },
      {
        "step": 6,
        "modelVersion": "chatgpt-gpt-5.2-2025-12-11",
        "toolCalls": [
          {
            "toolName": "glob",
            "input": {
              "pattern": "output/*.json",
              "dir_path": null,
              "case_sensitive": null,
              "respect_git_ignore": null,
              "respect_gemini_ignore": null
            },
            "output": "output/claim_audit.json\noutput/public_summary.json\noutput/quantitative_findings.json\noutput/study_overview.json",
            "callId": "call_gSigXQzXq2cCFRed2qxGlqcT"
          }
        ],
        "usage": {
          "promptTokens": 9082,
          "cachedTokens": 4480,
          "responseTokens": 43,
          "thinkingTokens": 0,
          "totalTokens": 9125
        },
        "costUsd": 0.0094395
      },
      {
        "step": 7,
        "modelVersion": "chatgpt-gpt-5.2-2025-12-11",
        "toolCalls": [
          {
            "toolName": "read_file",
            "input": {
              "file_path": "output/study_overview.json",
              "offset": 0,
              "limit": 200
            },
            "output": "L1: {\nL2:   \"paper\": {\nL3:     \"title\": \"SARS-CoV-2 mRNA vaccines sensitize tumours to immune checkpoint blockade\",\nL4:     \"doi\": \"10.1038/s41586-025-09006-8\",\nL5:     \"publication_year\": 2025,\nL6:     \"domain\": \"oncology-immunology\",\nL7:     \"study_type\": \"preclinical+retrospective\"\nL8:   },\nL9:   \"core_question\": \"Can intratumoral delivery of an mRNA vaccine induce an interferon-rich tumor state that improves sensitivity to anti-PD-L1 immune checkpoint blockade?\",\nL10:   \"datasets_or_cohorts\": [\nL11:     {\nL12:       \"id\": \"mouse-efficacy-combo\",\nL13:       \"label\": \"Mouse efficacy cohort (combination therapy)\",\nL14:       \"sample_size_or_observations\": \"78 tumor-bearing mice\",\nL15:       \"description\": \"Pooled murine tumor-model experiments testing intratumoral mRNA vaccination in combination with anti-PD-L1 treatment for tumor control.\"\nL16:     },\nL17:     {\nL18:       \"id\": \"mouse-controls\",\nL19:       \"label\": \"Mouse control cohort (vaccine only, ICI only, vehicle)\",\nL20:       \"sample_size_or_observations\": \"84 tumor-bearing mice\",\nL21:       \"description\": \"Matched murine control arms used to contextualize combination effects, including vaccine-only, ICI-only, and vehicle conditions.\"\nL22:     },\nL23:     {\nL24:       \"id\": \"human-retrospective-metastatic\",\nL25:       \"label\": \"Human retrospective metastatic cohort\",\nL26:       \"sample_size_or_observations\": \"130 patients\",\nL27:       \"description\": \"Retrospective analysis of metastatic patients receiving immune checkpoint inhibitor therapy, stratified by prior SARS-CoV-2 mRNA vaccination status.\"\nL28:     },\nL29:     {\nL30:       \"id\": \"human-vaccinated\",\nL31:       \"label\": \"Human vaccinated subgroup\",\nL32:       \"sample_size_or_observations\": \"43 patients\",\nL33:       \"description\": \"Subset of the retrospective metastatic cohort with documented prior SARS-CoV-2 mRNA vaccination exposure before or around ICI treatment.\"\nL34:     },\nL35:     {\nL36:       \"id\": \"human-unvaccinated\",\nL37:       \"label\": \"Human unvaccinated subgroup\",\nL38:       \"sample_size_or_observations\": \"87 patients\",\nL39:       \"description\": \"Subset of the retrospective metastatic cohort without prior SARS-CoV-2 mRNA vaccination, used as the comparison group for survival analyses.\"\nL40:     }\nL41:   ],\nL42:   \"major_limitations\": [\nL43:     \"Human analysis was retrospective and non-randomized, so residual confounding is likely.\",\nL44:     \"Vaccination timing relative to ICI initiation varied across patients.\",\nL45:     \"Tumor-type mix and treatment-history heterogeneity limit causal interpretation.\",\nL46:     \"Mouse model effects may not map one-to-one to all human tumors.\",\nL47:     \"Some mechanistic readouts were strongest in specific model systems rather than uniformly across all tested settings.\"\nL48:   ]\nL49: }",
            "callId": "call_CBtBnWMt8uN97VnA4iisBBGY"
          },
          {
            "toolName": "read_file",
            "input": {
              "file_path": "output/quantitative_findings.json",
              "offset": 0,
              "limit": 200
            },
            "output": "L1: {\nL2:   \"findings\": [\nL3:     {\nL4:       \"id\": \"Q01\",\nL5:       \"metric\": \"Fraction of tumor proteins represented in immunopeptidome\",\nL6:       \"value\": \"62.3%\",\nL7:       \"comparator_or_baseline\": \"37.3%\",\nL8:       \"interpretation\": \"Broader antigen display after intratumoral mRNA vaccination.\",\nL9:       \"evidence_line_refs\": [\nL10:         \"L28\"\nL11:       ]\nL12:     },\nL13:     {\nL14:       \"id\": \"Q02\",\nL15:       \"metric\": \"Fraction of proteins represented in MHC-I peptidome\",\nL16:       \"value\": \"40.6%\",\nL17:       \"comparator_or_baseline\": \"20.6%\",\nL18:       \"interpretation\": \"Strong expansion of the MHC-I-presented landscape.\",\nL19:       \"evidence_line_refs\": [\nL20:         \"L29\"\nL21:       ]\nL22:     },\nL23:     {\nL24:       \"id\": \"Q03\",\nL25:       \"metric\": \"Retrospective human survival comparison p-value\",\nL26:       \"value\": \"p=0.01\",\nL27:       \"comparator_or_baseline\": \"N/A\",\nL28:       \"interpretation\": \"Vaccinated subgroup had improved survival under ICI treatment.\",\nL29:       \"evidence_line_refs\": [\nL30:         \"L30\"\nL31:       ]\nL32:     },\nL33:     {\nL34:       \"id\": \"Q04\",\nL35:       \"metric\": \"Type I interferon response score (normalized units)\",\nL36:       \"value\": \"3.1\",\nL37:       \"comparator_or_baseline\": \"1.0\",\nL38:       \"interpretation\": \"Marked induction of type I interferon response after mRNA vaccination in tumors.\",\nL39:       \"evidence_line_refs\": [\nL40:         \"L31\"\nL41:       ]\nL42:     },\nL43:     {\nL44:       \"id\": \"Q05\",\nL45:       \"metric\": \"PD-L1 expression fold-change in tumor tissue\",\nL46:       \"value\": \"2.4x\",\nL47:       \"comparator_or_baseline\": \"1.0x\",\nL48:       \"interpretation\": \"Checkpoint axis became more targetable after vaccination.\",\nL49:       \"evidence_line_refs\": [\nL50:         \"L32\"\nL51:       ]\nL52:     },\nL53:     {\nL54:       \"id\": \"Q06\",\nL55:       \"metric\": \"Intratumoral CD8+ T-cell density fold-change\",\nL56:       \"value\": \"1.8x\",\nL57:       \"comparator_or_baseline\": \"1.0x\",\nL58:       \"interpretation\": \"Increased immune infiltration with combination therapy.\",\nL59:       \"evidence_line_refs\": [\nL60:         \"L33\"\nL61:       ]\nL62:     }\nL63:   ],\nL64:   \"controls_or_null_results\": [\nL65:     {\nL66:       \"statement\": \"Vaccine-only treatment did not produce durable tumor control in non-immunogenic models.\",\nL67:       \"evidence_line_ref\": \"L36\"\nL68:     },\nL69:     {\nL70:       \"statement\": \"ICI-only treatment had limited activity in low-immunogenic baseline settings.\",\nL71:       \"evidence_line_ref\": \"L37\"\nL72:     },\nL73:     {\nL74:       \"statement\": \"Lipid particle controls lacking mRNA did not reproduce the sensitization effect.\",\nL75:       \"evidence_line_ref\": \"L38\"\nL76:     },\nL77:     {\nL78:       \"statement\": \"Blocking type I interferon signaling with anti-IFNAR1 eliminated the observed sensitization benefit.\",\nL79:       \"evidence_line_ref\": \"L39\"\nL80:     }\nL81:   ]\nL82: }",
            "callId": "call_8SreFGH3Je9zFVW87DAQzHPj"
          },
          {
            "toolName": "read_file",
            "input": {
              "file_path": "output/claim_audit.json",
              "offset": 0,
              "limit": 120
            },
            "output": "L1: {\nL2:   \"claims\": [\nL3:     {\nL4:       \"claim_id\": \"C01\",\nL5:       \"claim\": \"Intratumoral mRNA vaccination is proposed to trigger type I interferon signaling and increase antigen processing/presentation in the tumor.\",\nL6:       \"strength\": \"moderate\",\nL7:       \"evidence\": [\nL8:         {\nL9:           \"quote\": \"Intratumoral mRNA vaccination triggers local innate sensing and type I interferon signaling.\",\nL10:           \"line_ref\": \"L42\"\nL11:         },\nL12:         {\nL13:           \"quote\": \"Interferon-associated antigen processing and presentation pathways increase.\",\nL14:           \"line_ref\": \"L43\"\nL15:         }\nL16:       ],\nL17:       \"caveat\": \"This is presented as a proposed mechanistic chain, and the report notes that some mechanistic readouts were strongest in specific model systems rather than uniformly across all tested settings.\"\nL18:     },\nL19:     {\nL20:       \"claim_id\": \"C02\",\nL21:       \"claim\": \"Intratumoral mRNA vaccination broadened tumor antigen display in immunopeptidomics (62.3% versus 37.3% of tumor proteins represented).\",\nL22:       \"strength\": \"strong\",\nL23:       \"evidence\": [\nL24:         {\nL25:           \"quote\": \"Fraction of tumor proteins represented in immunopeptidome | 62.3% | 37.3% | Broader antigen display after intratumoral mRNA vaccination\",\nL26:           \"line_ref\": \"L28\"\nL27:         },\nL28:         {\nL29:           \"quote\": \"A broader peptide repertoire appears on MHC-I, improving tumor visibility to T cells.\",\nL30:           \"line_ref\": \"L44\"\nL31:         }\nL32:       ],\nL33:       \"caveat\": \"The report cautions that mouse model effects may not map one-to-one to all human tumors, so the magnitude of peptide-display changes may differ across settings.\"\nL34:     },\nL35:     {\nL36:       \"claim_id\": \"C03\",\nL37:       \"claim\": \"Intratumoral mRNA vaccination expanded the fraction of proteins represented in the MHC-I peptidome (40.6% versus 20.6%).\",\nL38:       \"strength\": \"strong\",\nL39:       \"evidence\": [\nL40:         {\nL41:           \"quote\": \"Fraction of proteins represented in MHC-I peptidome | 40.6% | 20.6% | Strong expansion of MHC-I-presented landscape\",\nL42:           \"line_ref\": \"L29\"\nL43:         },\nL44:         {\nL45:           \"quote\": \"A broader peptide repertoire appears on MHC-I, improving tumor visibility to T cells.\",\nL46:           \"line_ref\": \"L44\"\nL47:         }\nL48:       ],\nL49:       \"caveat\": \"These measurements are drawn from preclinical tumor-model experiments, and the report notes that effects observed in mice may not translate directly across all human tumors.\"\nL50:     },\nL51:     {\nL52:       \"claim_id\": \"C04\",\nL53:       \"claim\": \"mRNA vaccination increased PD-L1 expression in tumor tissue (2.4×), supporting a rationale for combining vaccination with checkpoint blockade.\",\nL54:       \"strength\": \"moderate\",\nL55:       \"evidence\": [\nL56:         {\nL57:           \"quote\": \"PD-L1 expression fold-change in tumor tissue | 2.4x | 1.0x | Checkpoint axis became more targetable\",\nL58:           \"line_ref\": \"L32\"\nL59:         },\nL60:         {\nL61:           \"quote\": \"PD-L1 pathway activity also increases, creating a rationale for combining with checkpoint blockade.\",\nL62:           \"line_ref\": \"L45\"\nL63:         }\nL64:       ],\nL65:       \"caveat\": \"An increase in PD-L1 does not by itself prove improved clinical benefit, and the report emphasizes that prospective randomized studies are required before clinical protocol changes are justified.\"\nL66:     },\nL67:     {\nL68:       \"claim_id\": \"C05\",\nL69:       \"claim\": \"In a retrospective metastatic patient cohort receiving ICI therapy, prior SARS-CoV-2 mRNA vaccination was associated with improved survival (p=0.01).\",\nL70:       \"strength\": \"tentative\",\nL71:       \"evidence\": [\nL72:         {\nL73:           \"quote\": \"Translational arm: a retrospective cohort of metastatic patients receiving ICI treatment, compared by prior SARS-CoV-2 mRNA vaccination status.\",\nL74:           \"line_ref\": \"L15\"\nL75:         },\nL76:         {\nL77:           \"quote\": \"Retrospective human survival comparison p-value | p=0.01 | N/A | Vaccinated subgroup had improved survival under ICI treatment\",\nL78:           \"line_ref\": \"L30\"\nL79:         },\nL80:         {\nL81:           \"quote\": \"The human analysis is retrospective and non-randomized; residual confounding is likely.\",\nL82:           \"line_ref\": \"L49\"\nL83:         }\nL84:       ],\nL85:       \"caveat\": \"Because the analysis is retrospective with varied vaccination timing and heterogeneous tumor types/treatment histories, the observed association cannot be interpreted as causal.\"\nL86:     },\nL87:     {\nL88:       \"claim_id\": \"C06\",\nL89:       \"claim\": \"Blocking type I interferon signaling with anti-IFNAR1 eliminated the sensitization benefit attributed to intratumoral mRNA vaccination.\",\nL90:       \"strength\": \"strong\",\nL91:       \"evidence\": [\nL92:         {\nL93:           \"quote\": \"Blocking type I interferon signaling with anti-IFNAR1 eliminated the observed sensitization benefit.\",\nL94:           \"line_ref\": \"L39\"\nL95:         },\nL96:         {\nL97:           \"quote\": \"Intratumoral mRNA vaccination triggers local innate sensing and type I interferon signaling.\",\nL98:           \"line_ref\": \"L42\"\nL99:         }\nL100:       ],\nL101:       \"caveat\": \"This perturbation result is reported for the preclinical system, and the report notes that mouse model effects may not map one-to-one to all human tumors.\"\nL102:     }\nL103:   ]\nL104: }",
            "callId": "call_HJhLwQyLKlmaLO3vvxddfduU"
          },
          {
            "toolName": "read_file",
            "input": {
              "file_path": "output/public_summary.json",
              "offset": 0,
              "limit": 120
            },
            "output": "L1: {\nL2:   \"headline\": \"Intratumoral mRNA vaccination may prime tumors to respond better to anti-PD-L1 therapy\",\nL3:   \"plain_language_summary\": \"Immune checkpoint inhibitors (ICIs) can work well for some people with cancer, but many tumors do not respond because the immune system is not strongly activated against them. This study tested whether delivering an mRNA vaccine directly into a tumor can create a local, interferon-driven inflammatory environment that makes tumors easier for immune cells to recognize and attack. In mouse tumor models, the authors report broader presentation of tumor peptides on MHC-I \nL4:   \"what_is_new\": [\nL5:     \"Tests intratumoral mRNA vaccination as a way to induce an interferon-rich tumor microenvironment.\",\nL6:     \"Reports broader tumor peptide display on MHC-I after intratumoral mRNA vaccination in mice.\",\nL7:     \"Links prior SARS-CoV-2 mRNA vaccination to better survival under ICI in a retrospective cohort.\"\nL8:   ],\nL9:   \"why_caution_is_needed\": [\nL10:     \"The human cohort analysis is retrospective and non-randomized, so confounding could explain the association.\",\nL11:     \"Vaccination timing relative to starting checkpoint therapy varied across patients, complicating interpretation.\",\nL12:     \"Different tumor types and prior treatments were mixed together, limiting direct causal conclusions.\",\nL13:     \"Mouse tumor-model findings may not translate directly to all human cancers or clinical protocols.\"\nL14:   ],\nL15:   \"glossary\": [\nL16:     {\nL17:       \"term\": \"Immune checkpoint inhibitor (ICI)\",\nL18:       \"definition\": \"A cancer immunotherapy drug that releases brakes on T cells (for example, anti-PD-1 or anti-PD-L1) to help them attack tumors.\"\nL19:     },\nL20:     {\nL21:       \"term\": \"PD-L1\",\nL22:       \"definition\": \"A protein that can suppress T-cell activity by engaging PD-1; higher PD-L1 activity can make tumors targets for anti-PD-L1 drugs.\"\nL23:     },\nL24:     {\nL25:       \"term\": \"Type I interferon\",\nL26:       \"definition\": \"A family of innate immune signals that can drive inflammation and upregulate pathways involved in antigen processing and presentation.\"\nL27:     },\nL28:     {\nL29:       \"term\": \"MHC-I\",\nL30:       \"definition\": \"A cell-surface molecule that displays short peptide fragments to CD8+ T cells, helping the immune system recognize abnormal cells.\"\nL31:     },\nL32:     {\nL33:       \"term\": \"Immunopeptidome\",\nL34:       \"definition\": \"The set of peptides displayed on MHC molecules in a tissue; changes in the immunopeptidome can reflect altered antigen presentation.\"\nL35:     }\nL36:   ],\nL37:   \"open_questions\": [\nL38:     \"Would a prospective randomized trial confirm a causal benefit of vaccination-associated priming for ICI responses?\",\nL39:     \"Which tumor types and clinical contexts are most likely to show meaningful sensitization to checkpoint blockade?\",\nL40:     \"What dosing, timing, and delivery method for intratumoral mRNA would be feasible and safe in humans?\",\nL41:     \"How durable are the interferon and antigen-presentation changes, and do they correlate with long-term tumor control?\"\nL42:   ]\nL43: }",
            "callId": "call_FgSxw5YTswygxCFnPdcdkxIv"
          }
        ],
        "usage": {
          "promptTokens": 9158,
          "cachedTokens": 8960,
          "responseTokens": 131,
          "thinkingTokens": 0,
          "totalTokens": 9289
        },
        "costUsd": 0.0037485
      },
      {
        "step": 8,
        "modelVersion": "chatgpt-gpt-5.2-2025-12-11",
        "thoughts": "**Fixing JSON file issues**\n\nIt looks like the public_summary.json file is broken. The line cut at \"MHC-I\" suggests it might be missing parts of a string, probably due to a newline from the long string with write_file. I see that it's invalid JSON because line 3 ends mid-string. I need to rewrite it, ensuring the plain_language_summary is between 180-1200 characters and that what_is_new contains exactly 3 items. I'll check other files, but they seemed fine. Time to fix public_summary.",
        "toolCalls": [
          {
            "toolName": "write_file",
            "input": {
              "file_path": "output/public_summary.json",
              "content": "{\n  \"headline\": \"Intratumoral mRNA vaccination may prime tumors to respond better to anti-PD-L1 therapy\",\n  \"plain_language_summary\": \"Immune checkpoint inhibitors (ICIs) can work well for some people with cancer, but many tumors do not respond because the immune system is not strongly activated against them. This study tested whether delivering an mRNA vaccine directly into a tumor can create a local, interferon-driven inflammatory environment that makes tumors easier for immune cells to recognize and attack. In mouse tumor models, the authors report broader presentation of tumor peptides on MHC-I and increases in signals linked to immune activation, alongside increased PD-L1 pathway activity that could make anti-PD-L1 therapy more effective. The paper also includes a retrospective (non-randomized) analysis of 130 metastatic patients treated with ICIs, where prior SARS-CoV-2 mRNA vaccination was associated with improved survival (p=0.01). Because the human data are observational and vaccination timing and patient histories vary, the results support a hypothesis but do not prove that vaccination causes better outcomes; prospective randomized trials would be needed before changing clinical practice.\",\n  \"what_is_new\": [\n    \"Tests intratumoral mRNA vaccination as a way to induce an interferon-rich tumor microenvironment.\",\n    \"Reports broader tumor peptide display on MHC-I after intratumoral mRNA vaccination in mice.\",\n    \"Links prior SARS-CoV-2 mRNA vaccination to better survival under ICI in a retrospective cohort.\"\n  ],\n  \"why_caution_is_needed\": [\n    \"The human cohort analysis is retrospective and non-randomized, so confounding could explain the association.\",\n    \"Vaccination timing relative to starting checkpoint therapy varied across patients, complicating interpretation.\",\n    \"Different tumor types and prior treatments were mixed together, limiting direct causal conclusions.\",\n    \"Mouse tumor-model findings may not translate directly to all human cancers or clinical protocols.\"\n  ],\n  \"glossary\": [\n    {\n      \"term\": \"Immune checkpoint inhibitor (ICI)\",\n      \"definition\": \"A cancer immunotherapy drug that releases brakes on T cells (for example, anti-PD-1 or anti-PD-L1) to help them attack tumors.\"\n    },\n    {\n      \"term\": \"PD-L1\",\n      \"definition\": \"A protein that can suppress T-cell activity by engaging PD-1; higher PD-L1 activity can make tumors targets for anti-PD-L1 drugs.\"\n    },\n    {\n      \"term\": \"Type I interferon\",\n      \"definition\": \"A family of innate immune signals that can drive inflammation and upregulate pathways involved in antigen processing and presentation.\"\n    },\n    {\n      \"term\": \"MHC-I\",\n      \"definition\": \"A cell-surface molecule that displays short peptide fragments to CD8+ T cells, helping the immune system recognize abnormal cells.\"\n    },\n    {\n      \"term\": \"Immunopeptidome\",\n      \"definition\": \"The set of peptides displayed on MHC molecules in a tissue; changes in the immunopeptidome can reflect altered antigen presentation.\"\n    }\n  ],\n  \"open_questions\": [\n    \"Would a prospective randomized trial confirm a causal benefit of vaccination-associated priming for ICI responses?\",\n    \"Which tumor types and clinical contexts are most likely to show meaningful sensitization to checkpoint blockade?\",\n    \"What dosing, timing, and delivery method for intratumoral mRNA would be feasible and safe in humans?\",\n    \"How durable are the interferon and antigen-presentation changes, and do they correlate with long-term tumor control?\"\n  ]\n}\n"
            },
            "output": "Successfully wrote file: output/public_summary.json",
            "callId": "call_iElOWGkHQLrUY8Zk8X6GIdkJ"
          }
        ],
        "usage": {
          "promptTokens": 13161,
          "cachedTokens": 8960,
          "responseTokens": 842,
          "thinkingTokens": 200,
          "totalTokens": 14203
        },
        "costUsd": 0.02350775
      },
      {
        "step": 9,
        "modelVersion": "chatgpt-gpt-5.2-2025-12-11",
        "toolCalls": [
          {
            "toolName": "read_file",
            "input": {
              "file_path": "output/public_summary.json",
              "offset": 0,
              "limit": 60
            },
            "output": "L1: {\nL2:   \"headline\": \"Intratumoral mRNA vaccination may prime tumors to respond better to anti-PD-L1 therapy\",\nL3:   \"plain_language_summary\": \"Immune checkpoint inhibitors (ICIs) can work well for some people with cancer, but many tumors do not respond because the immune system is not strongly activated against them. This study tested whether delivering an mRNA vaccine directly into a tumor can create a local, interferon-driven inflammatory environment that makes tumors easier for immune cells to recognize and attack. In mouse tumor models, the authors report broader presentation of tumor peptides on MHC-I \nL4:   \"what_is_new\": [\nL5:     \"Tests intratumoral mRNA vaccination as a way to induce an interferon-rich tumor microenvironment.\",\nL6:     \"Reports broader tumor peptide display on MHC-I after intratumoral mRNA vaccination in mice.\",\nL7:     \"Links prior SARS-CoV-2 mRNA vaccination to better survival under ICI in a retrospective cohort.\"\nL8:   ],\nL9:   \"why_caution_is_needed\": [\nL10:     \"The human cohort analysis is retrospective and non-randomized, so confounding could explain the association.\",\nL11:     \"Vaccination timing relative to starting checkpoint therapy varied across patients, complicating interpretation.\",\nL12:     \"Different tumor types and prior treatments were mixed together, limiting direct causal conclusions.\",\nL13:     \"Mouse tumor-model findings may not translate directly to all human cancers or clinical protocols.\"\nL14:   ],\nL15:   \"glossary\": [\nL16:     {\nL17:       \"term\": \"Immune checkpoint inhibitor (ICI)\",\nL18:       \"definition\": \"A cancer immunotherapy drug that releases brakes on T cells (for example, anti-PD-1 or anti-PD-L1) to help them attack tumors.\"\nL19:     },\nL20:     {\nL21:       \"term\": \"PD-L1\",\nL22:       \"definition\": \"A protein that can suppress T-cell activity by engaging PD-1; higher PD-L1 activity can make tumors targets for anti-PD-L1 drugs.\"\nL23:     },\nL24:     {\nL25:       \"term\": \"Type I interferon\",\nL26:       \"definition\": \"A family of innate immune signals that can drive inflammation and upregulate pathways involved in antigen processing and presentation.\"\nL27:     },\nL28:     {\nL29:       \"term\": \"MHC-I\",\nL30:       \"definition\": \"A cell-surface molecule that displays short peptide fragments to CD8+ T cells, helping the immune system recognize abnormal cells.\"\nL31:     },\nL32:     {\nL33:       \"term\": \"Immunopeptidome\",\nL34:       \"definition\": \"The set of peptides displayed on MHC molecules in a tissue; changes in the immunopeptidome can reflect altered antigen presentation.\"\nL35:     }\nL36:   ],\nL37:   \"open_questions\": [\nL38:     \"Would a prospective randomized trial confirm a causal benefit of vaccination-associated priming for ICI responses?\",\nL39:     \"Which tumor types and clinical contexts are most likely to show meaningful sensitization to checkpoint blockade?\",\nL40:     \"What dosing, timing, and delivery method for intratumoral mRNA would be feasible and safe in humans?\",\nL41:     \"How durable are the interferon and antigen-presentation changes, and do they correlate with long-term tumor control?\"\nL42:   ]\nL43: }",
            "callId": "call_tXG1tNnDDBMwu80Pp5Eiq4CR"
          }
        ],
        "usage": {
          "promptTokens": 14017,
          "cachedTokens": 12672,
          "responseTokens": 30,
          "thinkingTokens": 0,
          "totalTokens": 14047
        },
        "costUsd": 0.00499135
      },
      {
        "step": 10,
        "modelVersion": "chatgpt-gpt-5.2-2025-12-11",
        "thoughts": "**Investigating JSON output issues**\n\nI’m considering if the plain language summary has unescaped newline characters due to content line length. We wrote the JSON string correctly without newlines besides \\n for formatting. The string should not have any \\n except at the end. However, I'm seeing that read_file shows it’s truncated. Maybe read_file has limits on line length and it cuts off text? It could be that the line continues but gets omitted in the output. This needs more digging!**Examining JSON truncation**\n\nI’m reflecting on the JSON format we created. It should have line 3 as an entire summary string, which could be quite long. The read_file function might truncate lines that exceed a certain length, cutting off the rest and then showing what's on line 4. So, even if the file still has the closing quote, the tool might not display it due to this truncation. I’ll need to consider re-reading with higher limits or using grep_search to validate the JSON structure.**Confirming JSON formatting**\n\nI’m thinking about how to read a file with smaller lines by using \\n escapes in the summary. However, JSON doesn't allow raw newlines within strings. If we split the summary into multiple lines directly in the file, that would be invalid. The best option is to use \\n escape sequences and keep the summary as a continuous string. I need to verify if the file is valid JSON because the read_file tool's truncation seems off. I’ll use grep_search for the pattern 'practice\\\\.\",' to check for the closing quote.",
        "toolCalls": [
          {
            "toolName": "grep_search",
            "input": {
              "pattern": "changing clinical practice",
              "dir_path": "output",
              "include": "public_summary.json",
              "exclude_pattern": null,
              "names_only": false,
              "max_matches_per_file": 5,
              "total_max_matches": 5
            },
            "output": "output/public_summary.json:3:  \"plain_language_summary\": \"Immune checkpoint inhibitors (ICIs) can work well for some people with cancer, but many tumors do not respond because the immune system is not strongly activated against them. This study tested whether delivering an mRNA vaccine directly into a tumor can create a local, interferon-driven inflammatory environment that makes tumors easier for immune cells to recognize and attack. In mouse tumor models, the authors report broader presentation of tumor peptides on MHC-I and increases in signals linked to immune activation, alongside increased PD-L1 pathway activity that could make anti-PD-L1 therapy more effective. The paper also includes a retrospective (non-randomized) analysis of 130 metastatic patients treated with ICIs, where prior SARS-CoV-2 mRNA vaccination was associated with improved survival (p=0.01). Because the human data are observational and vaccination timing and patient histories vary, the results support a hypothesis but do not prove that vaccination causes better outcomes; prospective randomized trials would be needed before changing clinical practice.\",",
            "callId": "call_uo86VSHQta3cHluLvbz5I6Oy"
          }
        ],
        "usage": {
          "promptTokens": 14807,
          "cachedTokens": 13824,
          "responseTokens": 57,
          "thinkingTokens": 700,
          "totalTokens": 15564
        },
        "costUsd": 0.01473745
      },
      {
        "step": 11,
        "modelVersion": "chatgpt-gpt-5.2-2025-12-11",
        "thoughts": "**Assessing JSON validity**\n\nI'm noticing that the `read_file` display is truncating long lines, which might cause issues with invalid JSON. It seems like line 3 ends with \"MHC-I\" followed by a newline, pointing to a possible display limitation. To ensure we have valid JSON, we need to check if the file content has any unescaped newlines, as JSON only allows escaped newlines. If the tool is inserting actual newlines in the view, it suggests the JSON might be prematurely ending, making it corrupted. I'll consider re-reading the file with a higher limit.**Investigating file issues**\n\nI’m trying to understand why `read_file` shows a break after \"MHC-I,\" followed by a line that starts with `\"what_is_new\": [` without a closing quote or comma. This suggests there might be an actual newline after \"MHC-I.\" However, grep_search shows that line 3 contains the full summary and ends correctly, indicating the file is likely fine. It seems `read_file` truncates lines due to length and mislabels the next line. This is confusing! I'll need to dig deeper to reconcile these outputs.**Clarifying grep_search and read_file**\n\nI’m realizing that `grep_search` displays full matches without truncation, while `read_file` likely truncates the display output. In `read_file`, line 3 ends with \"MHC-I\" and line 4 starts with `\"what_is_new\": [` suggesting there might be a literal newline after \"MHC-I.\" This could explain why `grep_search` shows a full match; it usually matches across lines unless specified otherwise. The match appears to start on line 3 but might extend to later lines as well. I'll need to confirm this further.**Validating JSON structure**\n\nI’m concluding that line 3 includes the whole string, indicating that no newline was inserted earlier. This suggests that the `read_file` UI truncates at a certain character count instead of reflecting actual newlines, so the JSON is likely valid. To verify, I could read additional lines around line 3 using an offset and limit to check if it continues, but an alternative approach is to use `grep_search` for the pattern `\"plain_language_summary\"` to see if the closing quote appears. I’ll go ahead and run that search.",
        "toolCalls": [
          {
            "toolName": "grep_search",
            "input": {
              "pattern": "^\\s*\"plain_language_summary\":",
              "dir_path": "output",
              "include": "public_summary.json",
              "exclude_pattern": null,
              "names_only": false,
              "max_matches_per_file": 5,
              "total_max_matches": 5
            },
            "output": "output/public_summary.json:3:  \"plain_language_summary\": \"Immune checkpoint inhibitors (ICIs) can work well for some people with cancer, but many tumors do not respond because the immune system is not strongly activated against them. This study tested whether delivering an mRNA vaccine directly into a tumor can create a local, interferon-driven inflammatory environment that makes tumors easier for immune cells to recognize and attack. In mouse tumor models, the authors report broader presentation of tumor peptides on MHC-I and increases in signals linked to immune activation, alongside increased PD-L1 pathway activity that could make anti-PD-L1 therapy more effective. The paper also includes a retrospective (non-randomized) analysis of 130 metastatic patients treated with ICIs, where prior SARS-CoV-2 mRNA vaccination was associated with improved survival (p=0.01). Because the human data are observational and vaccination timing and patient histories vary, the results support a hypothesis but do not prove that vaccination causes better outcomes; prospective randomized trials would be needed before changing clinical practice.\",",
            "callId": "call_kPXnmqdPmleax5nqrXzgNxgj"
          }
        ],
        "usage": {
          "promptTokens": 15084,
          "cachedTokens": 14720,
          "responseTokens": 63,
          "thinkingTokens": 721,
          "totalTokens": 15868
        },
        "costUsd": 0.014189
      },
      {
        "step": 12,
        "modelVersion": "chatgpt-gpt-5.2-2025-12-11",
        "toolCalls": [
          {
            "toolName": "read_file",
            "input": {
              "file_path": "output/public_summary.json",
              "offset": 0,
              "limit": 20
            },
            "output": "L1: {\nL2:   \"headline\": \"Intratumoral mRNA vaccination may prime tumors to respond better to anti-PD-L1 therapy\",\nL3:   \"plain_language_summary\": \"Immune checkpoint inhibitors (ICIs) can work well for some people with cancer, but many tumors do not respond because the immune system is not strongly activated against them. This study tested whether delivering an mRNA vaccine directly into a tumor can create a local, interferon-driven inflammatory environment that makes tumors easier for immune cells to recognize and attack. In mouse tumor models, the authors report broader presentation of tumor peptides on MHC-I \nL4:   \"what_is_new\": [\nL5:     \"Tests intratumoral mRNA vaccination as a way to induce an interferon-rich tumor microenvironment.\",\nL6:     \"Reports broader tumor peptide display on MHC-I after intratumoral mRNA vaccination in mice.\",\nL7:     \"Links prior SARS-CoV-2 mRNA vaccination to better survival under ICI in a retrospective cohort.\"\nL8:   ],\nL9:   \"why_caution_is_needed\": [\nL10:     \"The human cohort analysis is retrospective and non-randomized, so confounding could explain the association.\",\nL11:     \"Vaccination timing relative to starting checkpoint therapy varied across patients, complicating interpretation.\",\nL12:     \"Different tumor types and prior treatments were mixed together, limiting direct causal conclusions.\",\nL13:     \"Mouse tumor-model findings may not translate directly to all human cancers or clinical protocols.\"\nL14:   ],\nL15:   \"glossary\": [\nL16:     {\nL17:       \"term\": \"Immune checkpoint inhibitor (ICI)\",\nL18:       \"definition\": \"A cancer immunotherapy drug that releases brakes on T cells (for example, anti-PD-1 or anti-PD-L1) to help them attack tumors.\"\nL19:     },\nL20:     {",
            "callId": "call_HSIX6JGD5zgH6DStZom68qe8"
          }
        ],
        "usage": {
          "promptTokens": 15367,
          "cachedTokens": 14720,
          "responseTokens": 30,
          "thinkingTokens": 0,
          "totalTokens": 15397
        },
        "costUsd": 0.00412825
      },
      {
        "step": 13,
        "modelVersion": "chatgpt-gpt-5.2-2025-12-11",
        "thoughts": "**Investigating JSON truncation**\n\nI’m looking into a JSON corruption issue in the `read_file` function. It appears line 3 truncates at \"MHC-I\" while line 4 starts with \"what_is_new\" without proper closure. Interestingly, a grep search shows line 3 has the complete information. I wonder if the `read_file` function has a line length limit. It seems like it cuts at about 500 characters per line, which could explain why some details aren't showing. I should probably explore further to confirm the file's validity.**Checking JSON file validity**\n\nI noticed that `read_file` shows line 3 missing a closing quote before the newline. This could mean the display is truncated, but it’s possible the file is valid. To confirm this, we could read the file using an offset, but since the long line is still a single line, that won't help. Luckily, grep suggests the file contains the correct pattern with the closing quote, so it seems good as is. We still need to ensure that different fields in the public_summary schema meet their character limits and entry counts. We should keep following the rules during our two-phase process!**Verifying JSON discrepancies**\n\nIt seems we wrote the `public_summary` twice due to a suspected JSON issue, which may have been a false alarm. I need to check the `claim_audit` quotes to ensure they match exact report snippets. I see that line 28 includes a full row, but we added pipes and additional text. In the report, line 28 shows the content with leading and trailing pipes, but we started with \"Fraction...\" without the initial pipe. This doesn't meet the requirement for quoting exact snippets from the report.**Reviewing evidence snippets**\n\nI need to ensure that our schema includes quotes for evidence entries, as the task specifies that quotes must match exact report snippets. This applies to lines 29, 30, and 32. We previously removed the initial pipe, which isn't correct. I'll fix `claim_audit.json` to include the exact line snippets from the report. For line 15, we referenced \"Translational arm: a retrospective cohort,\" but that line actually starts with a leading \"-\". Similarly, line 49 is missing its leading \"-\", and we need to address that for list items, such as line 42, which begins with \"1.\" but we've omitted that as well.**Correcting evidence quotes**\n\nI see that I'm missing key details in my quotes for various lines. Lines 43 to 45 omit their leading numbers. Line 39 should include a leading \"-\". For line 28 and others, which start with \"|\", I need to ensure all quotes match the exact format from the report. I’ll rewrite `claim_audit.json` to have these accurate quotes. I'll double-check lines 25 to 33, including necessary leading characters and avoiding extra spaces. Additionally, I'll verify length requirements for the quantitative findings and ensure the public summary matches correctly. Finally, I'll proceed with writing the file!",
        "toolCalls": [
          {
            "toolName": "write_file",
            "input": {
              "file_path": "output/claim_audit.json",
              "content": "{\n  \"claims\": [\n    {\n      \"claim_id\": \"C01\",\n      \"claim\": \"Intratumoral mRNA vaccination is proposed to trigger type I interferon signaling and increase antigen processing/presentation in the tumor.\",\n      \"strength\": \"moderate\",\n      \"evidence\": [\n        {\n          \"quote\": \"1. Intratumoral mRNA vaccination triggers local innate sensing and type I interferon signaling.\",\n          \"line_ref\": \"L42\"\n        },\n        {\n          \"quote\": \"2. Interferon-associated antigen processing and presentation pathways increase.\",\n          \"line_ref\": \"L43\"\n        }\n      ],\n      \"caveat\": \"This is presented as a proposed mechanistic chain, and the report notes that some mechanistic readouts were strongest in specific model systems rather than uniformly across all tested settings.\"\n    },\n    {\n      \"claim_id\": \"C02\",\n      \"claim\": \"Intratumoral mRNA vaccination broadened tumor antigen display in immunopeptidomics (62.3% versus 37.3% of tumor proteins represented).\",\n      \"strength\": \"strong\",\n      \"evidence\": [\n        {\n          \"quote\": \"| Fraction of tumor proteins represented in immunopeptidome | 62.3% | 37.3% | Broader antigen display after intratumoral mRNA vaccination |\",\n          \"line_ref\": \"L28\"\n        },\n        {\n          \"quote\": \"3. A broader peptide repertoire appears on MHC-I, improving tumor visibility to T cells.\",\n          \"line_ref\": \"L44\"\n        }\n      ],\n      \"caveat\": \"The report cautions that mouse model effects may not map one-to-one to all human tumors, so the magnitude of peptide-display changes may differ across settings.\"\n    },\n    {\n      \"claim_id\": \"C03\",\n      \"claim\": \"Intratumoral mRNA vaccination expanded the fraction of proteins represented in the MHC-I peptidome (40.6% versus 20.6%).\",\n      \"strength\": \"strong\",\n      \"evidence\": [\n        {\n          \"quote\": \"| Fraction of proteins represented in MHC-I peptidome | 40.6% | 20.6% | Strong expansion of MHC-I-presented landscape |\",\n          \"line_ref\": \"L29\"\n        },\n        {\n          \"quote\": \"3. A broader peptide repertoire appears on MHC-I, improving tumor visibility to T cells.\",\n          \"line_ref\": \"L44\"\n        }\n      ],\n      \"caveat\": \"These measurements are drawn from preclinical tumor-model experiments, and the report notes that effects observed in mice may not translate directly across all human tumors.\"\n    },\n    {\n      \"claim_id\": \"C04\",\n      \"claim\": \"mRNA vaccination increased PD-L1 expression in tumor tissue (2.4x), supporting a rationale for combining vaccination with checkpoint blockade.\",\n      \"strength\": \"moderate\",\n      \"evidence\": [\n        {\n          \"quote\": \"| PD-L1 expression fold-change in tumor tissue | 2.4x | 1.0x | Checkpoint axis became more targetable |\",\n          \"line_ref\": \"L32\"\n        },\n        {\n          \"quote\": \"4. PD-L1 pathway activity also increases, creating a rationale for combining with checkpoint blockade.\",\n          \"line_ref\": \"L45\"\n        }\n      ],\n      \"caveat\": \"An increase in PD-L1 does not by itself prove improved clinical benefit, and the report emphasizes that prospective randomized studies are required before clinical protocol changes are justified.\"\n    },\n    {\n      \"claim_id\": \"C05\",\n      \"claim\": \"In a retrospective metastatic patient cohort receiving ICI therapy, prior SARS-CoV-2 mRNA vaccination was associated with improved survival (p=0.01).\",\n      \"strength\": \"tentative\",\n      \"evidence\": [\n        {\n          \"quote\": \"- Translational arm: a retrospective cohort of metastatic patients receiving ICI treatment, compared by prior SARS-CoV-2 mRNA vaccination status.\",\n          \"line_ref\": \"L15\"\n        },\n        {\n          \"quote\": \"| Retrospective human survival comparison p-value | p=0.01 | N/A | Vaccinated subgroup had improved survival under ICI treatment |\",\n          \"line_ref\": \"L30\"\n        },\n        {\n          \"quote\": \"- The human analysis is retrospective and non-randomized; residual confounding is likely.\",\n          \"line_ref\": \"L49\"\n        }\n      ],\n      \"caveat\": \"Because the analysis is retrospective with varied vaccination timing and heterogeneous tumor types/treatment histories, the observed association cannot be interpreted as causal.\"\n    },\n    {\n      \"claim_id\": \"C06\",\n      \"claim\": \"Blocking type I interferon signaling with anti-IFNAR1 eliminated the sensitization benefit attributed to intratumoral mRNA vaccination.\",\n      \"strength\": \"strong\",\n      \"evidence\": [\n        {\n          \"quote\": \"- Blocking type I interferon signaling with anti-IFNAR1 eliminated the observed sensitization benefit.\",\n          \"line_ref\": \"L39\"\n        },\n        {\n          \"quote\": \"1. Intratumoral mRNA vaccination triggers local innate sensing and type I interferon signaling.\",\n          \"line_ref\": \"L42\"\n        }\n      ],\n      \"caveat\": \"This perturbation result is reported for the preclinical system, and the report notes that mouse model effects may not map one-to-one to all human tumors.\"\n    }\n  ]\n}\n"
            },
            "output": "Successfully wrote file: output/claim_audit.json",
            "callId": "call_pY7VXXh9UUUDWlaCdf0VLvJT"
          }
        ],
        "usage": {
          "promptTokens": 15809,
          "cachedTokens": 15232,
          "responseTokens": 1351,
          "thinkingTokens": 1197,
          "totalTokens": 18357
        },
        "costUsd": 0.03934735
      },
      {
        "step": 14,
        "modelVersion": "chatgpt-gpt-5.2-2025-12-11",
        "text": "- [x] `output/study_overview.json` written\n- [x] `output/quantitative_findings.json` written\n- [x] `output/claim_audit.json` written\n- [x] `output/public_summary.json` written",
        "thoughts": "**Investigating JSON issues**\n\nIt seems that the `public_summary` read_file function is truncating mid-line due to a newline character, which is causing invalid JSON. Specifically, line 3 ends with \"MHC-I\" and then a newline before the closing quote, indicating an issue. We wrote the file correctly without a newline, but it still truncates at the same point. Maybe there's a literal newline in the middle? Since the output shows a cut-off at \"MHC-I,\" it suggests there's a character limit affecting the read_file function.**Examining line truncation issues**\n\nThere's a 60-line limit, and line 3 is quite large. This might be causing truncation in the tool display, possibly due to line wrapping. However, grep_search shows the line complete. It seems like read_file could be displaying a partial line because of an internal line limit. It also doesn’t show closing quotes or commas at line 3. I wonder if I can verify the JSON's validity without a parser by using grep to check for closing quotes and commas. The file appears valid; read_file might not display long lines properly, so I’ll assume it’s fine.**Evaluating JSON compliance**\n\nIt seems we're close to violating the guideline about writing output files only if there's a concrete JSON or schema problem. While I found a potential quote issue, it doesn’t seem to affect the JSON itself. The `claim_audit` schema requires exact quotes, and we’ve adjusted them to match the full line with proper punctuation. We're ensuring that `public_summary` aligns with the schema too. I need to validate items like `what_is_new`, `why_caution`, and `open_questions`—all look good! Lastly, I need to check evidence quotes for the minimum requirement of ten.**Reviewing quantitative findings**\n\nI’m checking the quantitative findings: each `evidence_line_refs` array can have a maximum of 3, and we have that covered. For findings, the minimum is 5, and we currently have 6. The controls requirement of at least 2 is also met, as we have 4. I need to ensure `additionalProperties` is false, and our objects have no extra keys. I’m also concerned about the `claim_audit` quotes matching exactly; I noted leading characters from the report and made sure our lines align, including the spaces that can affect the markdown.**Confirming outputs and validity**\n\nI need to ensure that spaces and formatting match in our quotes, especially for lines that include leading pipes. For instance, line 28 correctly reflects the original line with all spaces included. Lines 29, 30, and 32 follow a similar format, which is great! Now, I need to verify that the output directory contains the four required files. I should check that the `public_summary` file is valid JSON, especially since read_file appeared truncated. I’ll use grep to confirm closing quotes and commas. After all this, I can stop the tools and provide a completion checklist!",
        "toolCalls": [],
        "usage": {
          "promptTokens": 17176,
          "cachedTokens": 14720,
          "responseTokens": 60,
          "thinkingTokens": 1110,
          "totalTokens": 18346
        },
        "costUsd": 0.023253999999999997
      }
    ],
    "totalCostUsd": 0.24106530000000004
  }
}
